Navin Fluorine International Limited

QUARTERLY EARNINGS DEEP-DIVE ANALYSIS

Navin Fluorine International Ltd (NAVINFLUOR)
Q2 FY26 Performance Review

Report Date: November 1, 2025
Rating: BUY | Target Price: ₹5,930 (12-month) | Upside: 18–20%

EXECUTIVE SUMMARY DASHBOARD

Execution Score: 92/100
Quarter Surprise Factor: Strong Beat

Revenue: ₹758.42 Cr (Beat by 46% YoY, 5% QoQ)
Operating EBITDA: ₹246.17 Cr (Beat by 129% YoY, 19% QoQ)
PAT: ₹148.37 Cr (Beat by 152% YoY, 27% QoQ)

Investment Thesis Impact: Significantly Strengthened

Key Takeaway: Navin Fluorine delivered its strongest quarterly performance with record revenues and industry-leading 32.5% operating margins, driven by all three business segments firing simultaneously while announcing strategic capacity expansions worth ₹311.5 crores to capture growing opportunities in refrigerants and specialty chemicals.

STRATEGIC EXECUTION TRACKER

Promise vs. Performance Matrix

CDMO Revenue Target
Original Target: $100mn by FY27
Q2 FY26 Status: On track with 98% YoY growth; 96% revenue from commercialized molecules
Explanation: Management confirmed strong order book visibility through FY27; working with 35–50 molecules, 8–10 commercial

EBITDA Margin Guidance
Original Guidance: 25% sustainable margin
Q2 FY26 Status: 32.46% achieved in Q2 FY26
Explanation: Significantly exceeded guidance; 1,176 bps YoY expansion driven by product mix and operational leverage

Specialty Chemicals Growth
Original Target: Revenue visibility for FY26
Q2 FY26 Status: 39% YoY growth in Q2
Explanation: Strong performance with Fluoro-specialty plant commissioned December 2024 contributing meaningfully

HPP Capacity Utilization
Original Target: Optimize R32 plants
Q2 FY26 Status: 38% YoY revenue growth; both R32 plants at optimal capacity
Explanation: Exceeded expectations with strong demand and improved realizations

Capex Deployment
Original Guidance: ₹7,000–10,000 Mn over FY26–FY27E
Approved: ₹311.5 Cr — HFC expansion (₹236.5 Cr) and MPP debottlenecking (₹75 Cr)
Explanation: New capacities targeted for Q3 FY27 commissioning

MANAGEMENT CREDIBILITY SCORE — 88/100

Navin Fluorine's management has demonstrated exceptional credibility over the past eight quarters, consistently delivering on or exceeding guidance across multiple parameters. The company's progressive margin expansion from 20.7% in Q2 FY25 to 32.5% in Q2 FY26 validates management's operational execution capabilities.

The CDMO segment's trajectory toward the ambitious $100mn FY27 target remains on schedule with 98% YoY growth. Historical performance shows revenue CAGR improvement and successful commissioning of multiple plants on schedule, including the Fluoro-specialty plant in December 2024. Minor deductions stem from the aspirational nature of CDMO targets and dependency on customer molecule commercialization timelines outside management's direct control.

RESOURCE ALLOCATION EFFICIENCY

The company's capital deployment strategy demonstrates superior efficiency with clear prioritization.

The approved ₹236.5 crore investment in additional HFC capacity (15,000 MTPA R32 equivalent) at Surat directly addresses surging refrigerant demand, with both existing R32 plants already operating at optimal capacity. This expansion aligns with the global shift toward low-GWP refrigerants driven by the Kigali Amendment, positioning NFIL to capture accelerating market growth projected at 8.3% CAGR through 2032.

The ₹75 crore MPP debottlenecking at Dahej through subsidiary Navin Fluorine Advanced Sciences Limited targets operational bottlenecks to enhance throughput without proportional capital intensity.

Both projects target Q3 FY27 commissioning, creating a structured capacity ramp aligned with order book visibility. The company's decision to expand HFC capacity rather than new product lines reflects disciplined capital allocation toward proven, high-margin businesses with visible demand.

EARNINGS QUALITY & SUSTAINABILITY ASSESSMENT

CORE EARNINGS RECONCILIATION

Metric (₹ Crores) — Q2 FY26 Reported | Adjustments | Core Operating Earnings | Q2 FY25 | YoY Change

Revenue from Operations: 758.42 | – | 758.42 | 518.56 | +46.3%
Other Income: 18.21 | (18.21) | – | 3.86 | –
Total Revenue: 776.63 | – | 758.42 | 522.42 | +45.2%
Operating EBITDA: 246.17 | – | 246.17 | 107.35 | +129.3%
Depreciation: 36.58 | – | 36.58 | 27.90 | +31.1%
Interest: 30.30 | – | 30.30 | 13.86 | +118.6%
PBT: 264.38 | (18.21) | 246.17 | 118.51 | +107.7%
Tax: 66.01 | (4.53) | 61.48 | 13.49 | +355.7%
Core PAT: 148.37 | (13.68) | 134.69 | 58.82 | +129.0%
Core PAT Margin: 19.56% | – | 17.76% | 11.34% | +634 bps

The earnings quality analysis reveals exceptional sustainability with minimal adjustments required. Core operating earnings excluding other income grew 129% YoY, nearly matching reported PAT growth of 152%, indicating genuine operational performance rather than accounting engineering.

The tax rate normalized to 24.88% in Q2 FY26 from an unusually low 11.38% in Q4 FY24, reflecting consistent tax treatment going forward.

Interest costs increased to ₹30.30 crores from ₹13.86 crores YoY due to higher debt levels funding capacity expansion, yet the interest coverage ratio remains robust at 8.12x, demonstrating strong debt servicing capability.

CASH CONVERSION ANALYSIS

OPERATING CASH FLOW QUALITY

The company's H1 FY26 performance demonstrates strong cash generation characteristics.

Operating EBITDA of ₹452.96 crores for H1 FY26 represents a 118% increase over H1 FY25, significantly outpacing revenue growth of 42%, indicating improving cash profitability.

Operating margins expanded from 19.93% in H1 FY25 to 30.53% in H1 FY26 (1,060 bps improvement), reflecting enhanced cash generation per revenue rupee.

WORKING CAPITAL DYNAMICS

H1 FY26 saw working capital consumption of ₹108.69 crores compared to a release of ₹29.49 crores in H1 FY25, reflecting rapid growth-driven inventory and receivables build-up.

Despite this, the company generated ₹280.88 crores net operating cash flow (vs ₹213.87 crores in H1 FY25), demonstrating strong underlying cash generation.

Cash conversion efficiency (Operating CFO/EBITDA) stood at 62% for H1 FY26, healthy for a high-growth phase.

CAPEX INTENSITY & FREE CASH FLOW

H1 FY26 investing activities consumed ₹594.32 crores (vs ₹160.39 crores in H1 FY25), reflecting accelerated capacity expansion including:

• Fluoro-specialty plant commissioning
• cGMP4 facility construction
• AHF plant setup
• Maintenance capex

The company raised ₹342.94 crores from financing activities (primarily debt), indicating disciplined leverage to fund growth.

Cash and cash equivalents improved to ₹49.18 crores (Sept 2025) from ₹19.68 crores (March 2025).

QUALITY OF EARNINGS SCORE — 87/100

Navin Fluorine demonstrates high earnings quality with strong cash conversion, minimal non-operating income dependence (other income only 2.4% of total revenue), and genuine operational profit growth.

The primary consideration is elevated capex phase which will temporarily pressure free cash flow through FY27, though this represents value-creating investment rather than maintenance spending.

MARGIN SUSTAINABILITY ANALYSIS

GROSS MARGIN EVOLUTION

Period — Operating Margin % — YoY Change — QoQ Change

Q2 FY25 — 20.70% — – — –
Q1 FY26 — 28.51% — +575 bps YoY — –
Q2 FY26 — 32.46% — +1,176 bps YoY — +395 bps QoQ

The dramatic gross margin expansion to 32.46% in Q2 FY26 represents a multi-quarter trend rather than anomalous spike. Sequential improvement of 395 bps from Q1 FY26’s 28.51% validates sustainable momentum.

Five-year historical data shows operating profit margin progression: FY21 (27.5%) → FY22 (24.4%) → FY23 (26.5%) → FY24 (21.8%) → FY25 (22.7%), with Q2 FY26’s 32.46% representing a structural breakthrough.

OPERATING LEVERAGE INDICATORS

The company exhibits exceptional operating leverage with revenue growth of 46% YoY translating to EBITDA growth of 129% YoY, demonstrating a 2.8x leverage multiplier.

Employee costs as percentage of revenue declined despite absolute growth, suggesting productivity gains.

The margin expansion occurred across all three business segments simultaneously — HPP (+38% revenue), Specialty Chemicals (+39% revenue), and CDMO (+98% revenue) — indicating company-wide operational excellence.

PRICING POWER EVIDENCE

Management commentary indicated “improved realizations for refrigerants” alongside volume growth, demonstrating pricing power in the HPP segment.

The tight global R32 supply-demand environment, driven by regulatory phase-out of high-GWP refrigerants under the Kigali Amendment, provides structural pricing support.

The company’s integrated fluorine chemistry capabilities create competitive moats enabling premium pricing for specialty chemicals and CDMO services.

MARGIN SUSTAINABILITY OUTLOOK

The 32.46% operating margin achieved in Q2 FY26 appears sustainable with potential for further improvement.

Management upgraded guidance to “aiming for EBITDA margin closer to 30% for FY26” from the original 25%, with medium-term target of 28–30%.

However, investors should anticipate some margin moderation toward the 28–30% range as new capacities ramp up in FY27, with potential return to 32%+ levels by FY28 as assets reach optimal utilization.

REVENUE QUALITY ANALYSIS

SEGMENT-WISE REVENUE QUALITY

Segment — Revenue (₹ Cr) — % of Total — YoY Growth — Key Drivers — Revenue Quality

HPP (High Performance Products) — 404 — 53% — +38%
Both R32 plants at optimal capacity; improved refrigerant realizations
High — Recurring revenue from essential refrigerant products with pricing power

Specialty Chemicals — 220 — 29% — +39%
Fluoro-specialty plant (commissioned Dec’24) contributing; H2 FY26 purchase orders in place
High — Strong order visibility; technical complexity creates barriers

CDMO — 134 — 18% — +98%
96% revenue from commercialized molecules; 8–10 molecules in commercial stage
Very High — Long-term contracts, sticky customer relationships, high switching costs

ORGANIC GROWTH VALIDATION

Navin Fluorine’s 46% YoY revenue growth in Q2 FY26 is entirely organic, driven by capacity utilization optimization, new plant commissioning, and market share gains.

The company has not pursued inorganic growth through acquisitions, making this performance particularly impressive.

H1 FY26 revenue of ₹1,483.82 crores (42% YoY growth) validates sustained organic momentum.

EXPORT ORIENTATION

While exact export breakup wasn’t disclosed for Q2, the CDMO segment’s 96% export orientation and HPP/Specialty Chemicals’ significant export exposure suggests overall export mix of 55–65% of revenues.

This provides natural INR depreciation hedge and access to premium global pricing.

FORWARD-LOOKING STRATEGIC INTELLIGENCE

MANAGEMENT TONE ANALYSIS

Sentiment Assessment: Highly Bullish

The Q2 FY26 earnings call revealed decisively bullish management sentiment. Management’s confidence manifests through:

1. Aggressive Capacity Expansion: Announcing ₹311.5 crores capex immediately following stellar results signals conviction in demand sustainability
2. Target Reaffirmation: Maintaining $100mn CDMO FY27 target despite already strong growth demonstrates pipeline confidence
3. Margin Guidance Upgrade: Raising FY26 margin target from 25% to “closer to 30%” indicates sustained operational excellence

KEY MANAGEMENT QUOTES

“All three of our business verticals demonstrated good growth in Q2 FY26, establishing a positive outlook for H2 FY26. With a healthy order book visibility through FY27, we are confident in sustaining this momentum.”

“For FY26, we are aiming for an EBITDA margin closer to 30%, up from the original guidance of 25%.”

“Both R32 plants are operating at optimal capacity utilization. We are adding 15,000 MTPA HFC capacity at Surat to meet growing demand. Peak revenue potential is ₹600–825 crores per annum.”

LANGUAGE PATTERN ANALYSIS

Keyword — Strategic Implication

“Strong” / “Robust” — Broad-based confidence across segments
“Visibility” / “Order book” — Long-term revenue certainty through FY27
“Optimal capacity” — Supply constraints and pricing power
“On track” — Reaffirmation of ambitious targets
“Challenging” / “Headwinds” — Minimal usage indicating absence of defensive tone

COMPETITIVE POSITIONING SIGNALS

MARKET SHARE TRAJECTORY

Management commentary indicates Navin Fluorine is gaining market share across segments.

In HPP/refrigerants, the company’s 38% revenue growth significantly exceeds India’s refrigerant market growth estimates of 7–9%, implying share gains.

The company operates India’s largest integrated fluorine chemistry complex, providing structural advantages.

PEER BENCHMARKING

Metric — Navin Fluorine (Q2 FY26) — SRF Ltd (Q2 FY26) — Competitive Positioning

Revenue Growth YoY — 46% — 6% — Significantly outperforming larger peer
EBITDA Growth YoY — 129% — 56% — Superior operational leverage
Operating Margin — 32.5% — ~17.9% — Industry-leading margins
P/E Ratio — 72.3x — 54.6x — Premium valuation reflecting growth expectations

DIFFERENTIATION VS. COMPETITORS

1. Integrated Fluorine Complex: Fully integrated facility from raw materials to finished products provides cost advantages unmatched domestically
2. CDMO Capabilities: cGMP facilities and pharma-grade CDMO operations differentiate from commodity chemical players
3. R32 Leadership: With existing plants at optimal capacity and 15,000 MTPA expansion approved, NFIL positions as India’s capacity leader

INVESTMENT PRIORITY EVOLUTION

CAPITAL ALLOCATION FRAMEWORK

Management’s “hopper of projects competing for value creation” indicates disciplined capital allocation with ROIC-based project selection.

The HFC expansion received priority given:

• Proven demand (existing plants at optimal capacity)
• Clear market growth drivers (regulatory tailwinds)
• Near-term commissioning timeline (Q3 FY27)

R&D INVESTMENT

Capital allocation toward:

• Fluoro-specialty plant (₹540 crores)
• cGMP4 project Phase 1 (₹160 crores)
• Pipeline of 35–50 molecules with 8–10 commercial

M&A APPETITE

Management commentary did not indicate active M&A pursuits, with growth strategy focused on organic capacity expansion and brownfield projects.

RISK FACTOR EMERGENCE

NEW RISKS IDENTIFIED IN Q2 FY26

1. Elevated Capex Cycle: ₹7,000–10,000 million capex guidance pressures free cash flow
2. Execution Risk on Multiple Projects: Simultaneous commissioning complexity
3. CDMO Revenue Concentration: 35% contribution from single European MSA customer
4. Margin Sustainability Skepticism: Historical margin range 20–27% vs current 32.5%

RISK MITIGATION STRATEGIES

• Balanced segment portfolio (HPP, Specialty Chemicals, CDMO)
• Integrated fluorine complex backward integration
• Strong balance sheet with 8.12x interest coverage
• Phased capex approach

INDUSTRY CROSS-REFERENCE ANALYSIS

PEER BENCHMARKING DEEP-DIVE

Revenue Growth Comparison

Company — Q2 FY26 Revenue Growth YoY — Key Performance

Navin Fluorine — 46.3% — All segments strong; new capacity commissioning
SRF Limited — 6.3% — Chemicals +23% offset by weaker segments
Gujarat Fluorochemicals — Data pending — Historical mid-teens growth

Navin Fluorine’s 46% revenue growth dramatically outpaces direct peer SRF (6%) and broader specialty chemicals industry trends (10–15%), indicating company-specific execution excellence.

MARGIN TRAJECTORY BENCHMARKING

Company — Q2 FY26 Operating Margin — YoY Margin Change — Competitive Position

Navin Fluorine — 32.5% — +1,176 bps — Industry-leading
SRF Limited — ~17.9% — +560 bps — Below NFIL despite larger scale
Gujarat Fluorochemicals — Historical 25–28% — Pending Q2 data — Strong but below NFIL’s Q2

Navin Fluorine achieved industry-leading 32.5% operating margins, surpassing even premium specialty chemical players.

VALUATION MULTIPLES ANALYSIS

Company — P/E Ratio — EV/EBITDA (Est.) — Premium/Discount Rationale

Navin Fluorine — 72.3x — ~45–50x — Highest premium: fastest growth, margin expansion, CDMO potential
Pidilite Industries — 68.7x — ~45–50x — Quality premium for market leadership
Gujarat Fluorochemicals — 64.0x — ~40–45x — Fluorochemicals specialization premium
SRF Limited — 54.6x — ~30–35x — Lower growth, diversification discount

Navin Fluorine commands highest valuation justified by 46% revenue growth and 129% EBITDA growth.

SUPPLY CHAIN & MARKET DYNAMICS

RAW MATERIAL COST ENVIRONMENT

Navin Fluorine’s backward integration through India’s largest integrated fluorine chemistry complex provides strategic advantage.

This integration insulates NFIL from spot price volatility affecting less integrated competitors.

Management’s ability to expand margins to 32.5% despite global chemical industry challenges indicates effective cost management.

DEMAND PATTERNS & ORDER VISIBILITY

Management explicitly stated “order book visibility through FY27”, reflecting strong demand sustainability.

• HPP/Refrigerants — Structural demand growth driven by Kigali Amendment; 8.3% CAGR through 2032
• Specialty Chemicals — Purchase orders secured for H2 FY26
• CDMO — Strong order book pipeline till FY27 with 35–50 molecules

SUPPLY CHAIN CONSTRAINTS

Management’s decision to expand HFC capacity when existing plants operate at optimal capacity indicates supply-constrained market.

This tightness supports pricing power and elevated margins through FY26–FY27.

SECTOR TREND VALIDATION

Industry Trend — Sector Consensus — NFIL Q2 FY26 Evidence

Demand Recovery Post-Destocking — Gradual improvement — 46% growth exceeds trend
Margin Normalization — Return to 20–25% — 32.5% achieved
Export Growth — 20% annually — Strong export contribution
CDMO Opportunity — India gaining share — 98% CDMO growth
Refrigerant Transition — R32 adoption accelerating — Capacity constraint + expansion

Navin Fluorine is capturing opportunities significantly better than peers.

FINANCIAL PERFORMANCE DEEP-DIVE

CONSOLIDATED P&L ANALYSIS

QUARTERLY PERFORMANCE (QoQ & YoY)

P&L Item (₹ Crores) — Q2 FY26 — Q1 FY26 — Q2 FY25 — QoQ Change — QoQ % — YoY Change — YoY %

Revenue from Operations: 758.42 — 725.40 — 518.56 — +33.02 — +4.6% — +239.86 — +46.3%
Other Income: 18.21 — 13.91 — 3.86 — +4.30 — +30.9% — +14.35 — +371.8%
Total Income: 776.63 — 739.31 — 522.42 — +37.32 — +5.0% — +254.21 — +48.7%

Raw Materials: 312.90 — 307.71 — 223.98 — +5.19 — +1.7% — +88.92 — +39.7%
Employee Expenses: 73.04 — 77.57 — 76.95 — –4.53 — –5.8% — –3.91 — –5.1%
Other Expenses: 126.31 — 133.33 — 110.28 — –7.02 — –5.3% — +16.03 — +14.5%

Operating EBITDA: 246.17 — 206.79 — 107.35 — +39.38 — +19.0% — +138.82 — +129.3%
Operating Margin %: 32.46% — 28.51% — 20.70% — +395 bps — – — +1,176 bps — –

Depreciation: 36.58 — 34.21 — 27.90 — +2.37 — +6.9% — +8.68 — +31.1%
Interest: 30.30 — 27.88 — 13.86 — +2.42 — +8.7% — +16.44 — +118.6%

PBT (incl. other income): 264.38 — 220.70 — 118.51 — +43.68 — +19.8% — +145.87 — +123.1%
Tax: 66.01 — 53.53 — 13.49 — +12.48 — +23.3% — +52.52 — +389.3%

Effective Tax Rate %: 24.96% — 24.25% — 11.38% — +71 bps — – — +1,358 bps — –

PAT: 148.37 — 117.17 — 58.82 — +31.20 — +26.6% — +89.55 — +152.2%
PAT Margin %: 19.56% — 16.15% — 11.34% — +341 bps — – — +822 bps — –

KEY OBSERVATIONS

1. Revenue Acceleration: Sequential growth of 4.6% with YoY growth of 46.3% indicates sustained demand
2. Margin Expansion Leadership: Operating margin improvement of 395 bps QoQ and 1,176 bps YoY reflects exceptional leverage
3. Profit Growth Outpacing Revenue: PAT growth of 152% YoY vs revenue 46% YoY demonstrates 3.3x leverage
4. Tax Normalization: Effective tax rose to 24.96% from abnormally low 11.38%
5. Interest Cost Pressure: Interest up 119% YoY, though coverage remains strong at 8.12x

HALF-YEAR PERFORMANCE (H1 FY26 VS H1 FY25)

Metric (₹ Crores) — H1 FY26 — H1 FY25 — YoY Change — YoY %

Revenue from Operations: 1,483.82 — 1,042.24 — +441.58 — +42.4%
Operating EBITDA: 452.96 — 207.72 — +245.24 — +118.1%
Operating Margin %: 30.53% — 19.93% — +1,060 bps — –
PAT: 265.54 — 108.87 — +156.67 — +143.9%
PAT Margin %: 17.90% — 10.44% — +746 bps — –

H1 FY26 performance validates Q2 as part of sustained trend rather than anomalous quarter.

BALANCE SHEET ANALYSIS

CONSOLIDATED BALANCE SHEET HIGHLIGHTS (AS OF SEPTEMBER 30, 2025)

Item (₹ Crores) — Sept 2025 — March 2025 — Change — Key Insight

Total Assets: 4,071.53 — 3,687.61 — +10.4% — Asset base expanding with capex
Equity Share Capital: 9.92 — 9.91 — Stable — No dilution
Reserves & Surplus: 2,487.46 — 2,272.79 — +9.4% — Retained earnings
Total Shareholder Funds: 2,497.38 — 2,282.70 — +9.4% — Equity strengthening
Long-term Debt: 1,053.44 — 1,022.86 — +3.0% — Modest capex funding
Total Debt: 1,440.73 — 1,339.94 — +7.5% — Capacity expansion
Cash & Cash Equivalents: 49.18 — 19.68 — +150% — Strong liquidity
Net Debt: ~1,391 — ~1,320 — +5.4% — Manageable increase

CAPITAL STRUCTURE ANALYSIS

Debt/Equity: 0.58x → 0.59x (Healthy)
Net Debt/Equity: 0.56x → 0.58x (Conservative)
Interest Coverage: 8.12x (Strong)

BALANCE SHEET STRENGTH ASSESSMENT

1. Conservative Leverage: Net debt-to-equity of 0.56x provides substantial headroom for growth capex
2. Asset Quality: Total assets grew 10.4% to ₹4,071.53 crores, driven by productive capacity additions
3. Equity Accretion: Reserves increased ₹214.67 crores in H1 FY26 through retained profits, strengthening equity base
4. Liquidity Position: Cash more than doubled to ₹49.18 crores, demonstrating strong working capital management

CASH FLOW STATEMENT ANALYSIS

H1 FY26 CASH FLOW PERFORMANCE

Cash Flow Component (₹ Crores) — H1 FY26 — H1 FY25 — YoY Change — Analysis

Profit Before Tax: 352.61 — 145.05 — +143% — Strong earnings growth

Adjustment for Non-Operating Items: 102.75 — 78.07 — +32% — Primarily depreciation

Operating Profit before Working Capital Changes: 455.36 — 223.12 — +104% — Robust operational cash generation

Changes in Working Capital: (108.69) — 29.49 — Outflow reflecting growth-driven inventory and receivables build-up

Cash Generated from Operations: 346.67 — 252.61 — +37% — Healthy despite working capital consumption

Less: Direct Taxes Paid: (65.79) — (38.74) — +70% — Higher tax outflow on elevated profits

Net Operating Cash Flow: 280.88 — 213.87 — +31% — Strong cash conversion

Cash Flow from Investing Activities: (594.32) — (160.39) — (271%) — Accelerated capex deployment

Cash Flow from Financing Activities: 342.94 — (51.08) — Positive swing due to debt drawdown and equity proceeds

Net Cash Change: 29.50 — 2.40 — +1,129% — Positive despite heavy capex

KEY CASH FLOW INSIGHTS

1. Operating CFO Strength: ₹280.88 crores net operating cash flow (H1 FY26) represents 62% conversion of EBITDA, healthy for growth phase
2. Working Capital Pressure: ₹108.69 crores working capital consumption reflects rapid growth; DSO/DIO likely elevated but manageable
3. Capex Intensity: ₹594.32 crores investing outflow (H1 FY26) includes:
   • Fluoro-specialty plant commissioning
   • cGMP4 facility construction
   • AHF plant setup
   • Maintenance capex
4. Balanced Funding: ₹342.94 crores financing inflow suggests mix of debt drawdown and potential QIP proceeds
5. Free Cash Flow: Operating CFO ₹281 Cr minus capex ₹594 Cr equals negative ₹313 Cr FCF in H1 FY26 — expected during expansion phase

CASH CONVERSION CYCLE ANALYSIS

While specific DSO/DIO/DPO data wasn’t disclosed, directional indicators suggest:

• Receivables: Likely increased with 42% H1 revenue growth
• Inventory: Raw material and finished goods buildup for H2 FY26 demand
• Payables: Managed prudently to maintain supplier relationships
• Net Impact: ₹108.69 Cr working capital consumption equals approximately 7.3% of H1 revenue (acceptable)

SEGMENT-WISE PERFORMANCE ANALYSIS

Q2 FY26 SEGMENT PERFORMANCE

Segment — Revenue (₹ Cr) — % of Total — YoY Growth — Key Performance Drivers

High Performance Products (HPP) — 404 — 53% — +38%
Both R32 plants at optimal capacity; improved refrigerant realizations; strong domestic and export demand

Specialty Chemicals — 220 — 29% — +39%
Fluoro-specialty plant contribution; H2 FY26 purchase orders secured; premium product mix

CDMO — 134 — 18% — +98%
96% revenue from commercialized molecules; European MSA order execution; 8–10 molecules commercial

Total — 758 — 100% — +46%
All segments firing simultaneously

SEGMENT DEEP-DIVE

HPP (High Performance Products) — ₹404 Crores (53% of revenue)

Performance Highlights:
• Growth: 38% YoY — exceeding refrigerant market growth of 7–9%
• Capacity: Both R32 plants operating at optimal utilization (95%+ estimated)
• Pricing Power: Improved realizations alongside volume growth
• Geographic Mix: Balanced domestic and export demand

Strategic Significance:
• Stable cash flow foundation
• Justifies ₹236.5 Cr HFC expansion
• Regulatory tailwinds from Kigali Amendment

Specialty Chemicals — ₹220 Crores (29% of revenue)

Performance Highlights:
• Growth: 39% YoY
• Fluoro-specialty plant commissioned December 2024 contributing
• Purchase orders secured for H2 FY26
• Estimated 30–35% EBITDA margins

Strategic Significance:
• Premium pricing
• Technical barriers to entry
• Export orientation

CDMO — ₹134 Crores (18% of revenue)

Performance Highlights:
• Growth: 98% YoY
• 96% revenue from commercialized molecules
• 35–50 molecule pipeline, 8–10 commercial
• Predominantly US/Europe exports

Strategic Significance:
• Highest margin segment (35–40% EBITDA estimated)
• Sticky long-term contracts
• Anchor European MSA customer

KEY FINANCIAL RATIOS & TRENDS

PROFITABILITY RATIOS

Ratio — Q2 FY26 — Q2 FY25 — FY25 — 5-Year Trend

Gross Profit Margin: 58.7% — 56.8% — 57.2% — Improving
Operating Margin (EBITDA): 32.5% — 20.7% — 22.7% — Steep expansion
Net Profit Margin: 19.6% — 11.3% — 12.8% — Rapid expansion
Return on Equity (ROE): ~24% (annualized) — 11.5% — 11.5% — Inflecting upward
Return on Capital Employed (ROCE): ~27% (annualized) — 14.8% — 15.2% — Strong improvement

EFFICIENCY RATIOS

Ratio — Current — Historical Trend

Asset Turnover: 1.9x (annualized) — Improving with new capacity utilization
Interest Coverage: 8.12x — Significantly strengthened
Tax Rate: 24.9% — Normalized

LEVERAGE & LIQUIDITY RATIOS

Ratio — Sept 2025 — March 2025 — Industry Benchmark — Assessment

Debt/Equity: 0.58x — 0.59x — 0.5–0.8x — Healthy
Net Debt/EBITDA: 1.19x (FY25) — 1.49x (FY24) — <2.5x — Conservative
Current Ratio: ~1.3x (est.) — ~1.2x — >1.0x — Adequate

GROWTH METRICS

Metric — CAGR FY22–FY25 — Projected FY25–FY28E — Acceleration

Revenue: 14.2% — 26–28% — Yes (Nearly doubled)
EBITDA: 12.8% — 37–40% — Yes (Tripling growth rate)
PAT: 8.3% — 37–40% — Yes (4–5x acceleration)
EPS: 8.1% — 37% — Yes (Structural shift)

QUALITY METRICS

Metric — Score — Benchmark — Interpretation

Cash Conversion (OCF/EBITDA): 62% (H1 FY26) — >50% — Healthy
Piotroski F-Score: 8/9 (estimated) — >7 — High quality
Altman Z-Score: >3.0 (estimated) — >2.6 — Low distress risk

MANAGEMENT COMMENTARY INSIGHTS

KEY MANAGEMENT QUOTES & STRATEGIC INTERPRETATION

On Q2 Performance & Outlook

“All three of our business verticals demonstrated good growth in Q2 FY26, establishing a positive outlook for H2 FY26. With a healthy order book visibility through FY27, we are confident in sustaining this momentum.”

Strategic Interpretation: This signals multi-year revenue certainty rare in specialty chemicals. The explicit “FY27 visibility” indicates signed contracts or purchase orders extending 2.5 years forward.

On Margin Sustainability (Critical Upgrade)

“For FY26, we are aiming for an EBITDA margin closer to 30%, up from the original guidance of 25%.”

Strategic Interpretation: The 500 bps guidance upgrade indicates structural margin improvement, not cyclical spike.

On HFC Capacity Expansion Decision

“Both R32 plants are operating at optimal capacity utilization. We are adding 15,000 MTPA HFC capacity (R32 equivalent) at Surat to meet growing demand. Peak revenue potential is ₹600–825 crores per annum.”

Strategic Interpretation: Signals tight supply-demand and strong pricing power.

On CDMO Business — $100mn Target Confidence

“CDMO segment delivered 98% YoY growth with 96% of revenue from commercialized molecules. We reaffirm our USD 100mn revenue target for FY27.”

Strategic Interpretation: CDMO has transitioned from potential to realized business model.

ON NEW PRODUCT LAUNCHES

“We have 2 molecules in the pipeline — one expected in Q4 FY25 and next in Q1 FY26. The cGMP4 facility validation batches have been initiated, with supplies to European client expected to commence by January 2026.” — Management

Strategic Interpretation: Each new CDMO molecule typically generates ₹30–50 crores initially, scaling to ₹100+ crores at peak. Two near-term launches plus cGMP4 commercialization creates ₹150–200 crore incremental revenue visibility for FY26–27.

TONE ANALYSIS — BULLISH INDICATORS

• Frequency of “strong” / “robust”: Used 15+ times across earnings call
• Absence of hedging language: No mentions of “challenging environment,” “headwinds,” or “uncertain outlook” — stark contrast to industry peers
• Proactive capacity additions: Announcing ₹311.5 crores new capex immediately post-results indicates internal confidence exceeds public statements

RISK-REWARD ASSESSMENT

BULL CASE (60% Probability) - Target: ₹6,500-7,000 by Dec 2026

1. CDMO Inflection Point Realized

• Catalyst: $100mn FY27 target achieved (₹850+ crores at current exchange rates)
• Impact: CDMO reaches 30-35% of total revenue (from current 18%), structurally elevating consolidated margins to 30%+ sustainably
• Revenue Mix Transformation: CDMO's 96% export orientation + 35-40% EBITDA margins drives consolidated margin expansion
• Valuation Re-rating: Market assigns 50-60x P/E to CDMO segment (pharma CDMO multiple) vs. current blended 40x, unlocking ₹3,000-5,000 crores incremental market cap

2. Margin Expansion Proves Structural

• Catalyst: Q3-Q4 FY26 EBITDA margins sustain at 30-32% range, validating Q2 wasn't cyclical peak
• Impact: FY26 full-year EBITDA margin exits at 29-30% (vs. historical 22-23%), driving 60-70% earnings CAGR FY25-27E
• Earnings Upgrade Cycle: Current consensus FY27E EPS of ₹124 upgrades to ₹145-155 as analysts model higher sustainable margins
• Valuation Support: Premium valuation (72x P/E) justified by 37% net income CAGR projection FY25-28E

3. New Capacity Commissioning Drives FY28 Re-rating

• Catalyst: HFC expansion (Q3 FY27) + MPP debottlenecking (Q3 FY27) + cGMP4 Phase 1 commercializing
• Impact: Combined ₹900-1,100 crores incremental revenue potential by FY28
• Near-term De-risking: HFC capacity is pre-sold (management confirmed growing demand necessitated expansion) - zero demand risk
• Multiple Expansion: As FY27 commissioning approaches, market starts discounting FY28 earnings, driving 12-18 month forward re-rating

BEAR CASE (25% Probability) - Downside: ₹4,200-4,500

1. Margin Compression Post-Capacity Addition

• Risk: New HFC capacity (Q3 FY27) experiences 12-18 month ramp-up with lower utilization, dragging consolidated margins to 26-28% in FY27
• Impact: Market reprices from 32% peak margins to 27-28% normalized margins, compressing valuation multiple to 55-60x P/E
• Trigger: Q1 FY27 results show margin dip as new capacities commission but don't immediately reach optimal utilization

2. CDMO Customer Concentration Risk

• Risk: Single European MSA customer contributing 35-40% of $100mn target faces regulatory delays or commercial setbacks
• Impact: $100mn FY27 target pushed to FY28, disappointing market expectations and triggering 10-15% stock correction
• Probability: Low (15-20%) - Management's track record of 100% molecule commercialization success mitigates this risk

3. Valuation Multiple Compression

• Risk: At 72x P/E (vs. sector average 40-50x), NFIL trades at significant premium. Any growth disappointment triggers de-rating to 55-60x P/E
• Impact: Even with earnings growth, stock could correct 10-15% if multiple compresses from 72x to 60x
• Trigger: Broader market correction or specialty chemicals sector revaluation

BASE CASE (Most Likely - 70% Probability) - Target: ₹5,600-6,000 by Sept 2026

Scenario: NFIL sustains 28-30% EBITDA margins through FY26-27, achieves $80-90mn CDMO revenue by FY27 (slightly below $100mn target), successfully commissions new capacities with 12-15 month ramp-up period.

Financial Outcomes:

• FY26E: Revenue ₹3,000 crores (+28% YoY), EBITDA ₹860 crores (28.7% margin), PAT ₹500 crores (+73% YoY)
• FY27E: Revenue ₹3,625 crores (+21% YoY), EBITDA ₹1,044 crores (28.8% margin), PAT ₹616 crores (+23% YoY)
• FY28E: Revenue ₹4,300 crores (+19% YoY), EBITDA ₹1,265 crores (29.4% margin), PAT ₹772 crores (+25% YoY)

Valuation Path:

• Current (Nov 2025): ₹5,200 @ 49.6x FY26E EPS
• Target (Sept 2026): ₹5,600-6,000 @ 40-45x FY27E EPS of ₹124
• Upside: 15-20% capital appreciation + 0.4-0.5% dividend yield

Key Assumptions:

1. No major macroeconomic disruptions affecting specialty chemicals demand
2. Successful cGMP4 commercialization and European MSA order execution
3. HFC and MPP capacity expansions commissioned on schedule (Q3 FY27)
4. Margins sustain in 28-30% band (not reverting to historical 22-23%)

CATALYST TIMELINE & WATCH ITEMS (LOSSLESS)

Near-Term Catalysts (0–6 months) — November 2025 to April 2026

Timeline — Catalyst Event — Expected Impact — Watch Items — Risk/Opportunity

Q3 FY26 (Oct–Dec 2025)
AHF plant commissioning

+₹30–40 Cr quarterly revenue; backward integration for HF reduces costs by 100–150 bps

(1) Production ramp-up speed
(2) Quality certifications obtained
(3) Captive consumption vs. merchant sales mix

Opportunity: Early stabilization could add ₹120–150 Cr FY26 revenue

January 2026
cGMP4 European client supplies commence

+₹20–30 Cr Q4 FY26 revenue; validates European MSA partnership

(1) Initial order size
(2) Product quality acceptance
(3) Follow-on order guidance

Risk: Any delay pushes FY27 CDMO target achievement

Q3 FY26 Results (Jan 2026)
Margin sustainability validation

Market confirms 30%+ margins aren’t Q2 anomaly

(1) Q3 EBITDA margin vs. Q2’s 32.5%
(2) Management FY26 full-year guidance
(3) Order book commentary

Key Decision Point:
Margin <28% triggers bear case

30% validates bull case and analyst upgrades

Feb–Mar 2026
Q4 FY25 new CDMO molecule launch

+₹8–12 Cr quarterly revenue initially, scaling to ₹40–50 Cr annually

(1) Customer identity (pharma/agro)
(2) Molecule application (indication of market size)
(3) Ramp-up timeline

Opportunity: Faster ramp-up accelerates $100mn target

March 2026
FY26 Annual Results

Full-year margin profile, FY27 guidance, capex update

(1) FY26 revenue vs. ₹3,000 Cr estimate
(2) EBITDA margin: 28–30% validation
(3) FY27 capex guidance

Major Catalyst: Strong FY26 exit with raised guidance = 15–20% stock upside

Medium-Term Catalysts (6–18 months) — May 2026 to April 2027

Timeline — Strategic Milestone — Revenue/Margin Impact — Critical Success Factors

Q1 FY27 (Apr–Jun 2026)
New CDMO molecule launch #2 (Q1 FY26 guided)

+₹10–15 Cr quarterly initially

Customer commercialization commitment; competitive landscape

H1 FY27 (Apr–Sep 2026)
CDMO business approaching $70–80mn run-rate

Validates path to $100mn FY27 target

European MSA order scaling (35–40% of target); new customer additions

Q2 FY27 (Jul–Sep 2026)
HFC expansion construction completion

₹236.5 Cr capex deployed; pre-commissioning activities

On-time, on-budget execution; customer pre-commitments for new capacity

Q3 FY27 (Oct–Dec 2026)
MAJOR: HFC Capacity Commissioning

+₹150–200 Cr quarterly revenue at peak (12–18 month ramp)

(1) Plant startup smoothness
(2) Initial utilization rates
(3) Pricing vs. existing capacity

Q3 FY27 (Oct–Dec 2026)
MAJOR: MPP Debottlenecking Completion

+₹35–40 Cr quarterly revenue at peak

Throughput improvement % achieved; product quality consistency

Q4 FY27 (Jan–Mar 2027)
FY27 Annual Results — $100mn CDMO Target Assessment

Validates/misses management’s flagship guidance

Make-or-break catalyst for management credibility

Quarterly Watch Items Checklist

Every Quarter — Monitor These KPIs

Revenue Growth (YoY)
• Bull Case: >25%
• Bear Case: <15%
• Neutral: 15–25%

Operating EBITDA Margin
• Bull Case: >30%
• Bear Case: <26%
• Neutral: 26–30%

CDMO Revenue Growth
• Bull Case: >50% YoY
• Bear Case: <30% YoY
• Neutral: 30–50%

HPP Segment Revenue
• Bull Case: Sequential growth
• Bear Case: Sequential decline
• Neutral: Flat QoQ

Order Book Commentary
• Bull Case: “Extended visibility beyond FY27”
• Bear Case: “Near-term visibility only”
• Neutral: “FY27 visibility maintained”

Capex Spend vs. Plan
• Bull Case: >80% of guided spend (execution confidence)
• Bear Case: <50% (delays signal issues)
• Neutral: 50–80%

Free Cash Flow
• Bull Case: Positive despite capex
• Bear Case: Negative beyond capex needs
• Neutral: Breakeven to slightly negative

Management Tone
• Bull Case: Raising guidance/targets
• Bear Case: Hedging/cautious language
• Neutral: Reaffirming guidance

Red Flags to Watch (Sell Signals)

1. CDMO customer loss: Any disclosure of major customer molecule discontinuation
2. Margin collapse: EBITDA margin falling below 25% for 2+ consecutive quarters
3. Capex delays: HFC/MPP commissioning pushed beyond Q4 FY27
4. Working capital blow-out: DSO >80 days or inventory days >90
5. Management credibility damage: Missing $100mn CDMO FY27 target by >20%
6. Regulatory issues: FDA/EMA warning letters for CDMO facilities

Green Flags to Accumulate (Buy Signals)

1. Margin sustainability: 3+ consecutive quarters of 30%+ EBITDA margins
2. CDMO acceleration: Quarterly growth >70% YoY sustained through FY26
3. Early capacity utilization: New HFC capacity >60% within 6 months
4. New customer wins: Additional European/US pharma CDMO partnerships
5. Technology partnerships: Validation deals similar to Chemours
6. Capacity expansion announcements before Phase 1 completion

INVESTMENT RECOMMENDATION

RATING: BUY (Upgraded from HOLD)

Target Price: ₹5,930 (12-month horizon, September 2027)
Upside Potential: 18–20% from current levels of ₹5,000–5,200
Investment Horizon: 12–18 months
Risk Rating: MEDIUM-HIGH
Portfolio Fit: Growth + Quality

Recommendation Rationale

Core Investment Thesis:

Navin Fluorine is undergoing a structural business model transformation from a refrigerant-focused chemical company to a diversified specialty chemicals + pharma CDMO platform with industry-leading margins and visible multi-year growth. The Q2 FY26 results represent an inflection point, not a cyclical peak, driven by:

1. CDMO Commercialization: Transition from development to commercial-scale manufacturing (96% of CDMO revenue from commercial molecules) creates high-margin, sticky revenue streams
2. Margin Re-rating: 32.5% operating margin achievement and management guidance upgrade to 28–30% (from 25%) indicates permanent margin structure improvement
3. Capacity-led Growth: ₹311.5 crores new capex (HFC + MPP) with pre-sold capacity and FY27 commissioning creates visible FY28–29 earnings acceleration
4. Order Book Visibility: Explicit “visibility through FY27” provides 2.5-year earnings certainty rare in chemicals sector

Valuation Justification

Current Valuation (November 2025):

• CMP: ₹5,200
• Market Cap: ₹25,700 crores
• FY26E P/E: 49.6x (on ₹101 EPS estimate)
• FY27E P/E: 40.4x (on ₹124 EPS estimate)

Target Valuation (September 2027):

• Target Price: ₹5,930
• Methodology: 40x FY27E (Sept 2027) EPS of ₹148 (upgraded from consensus ₹124 assuming margin sustainability)
• Implied Sept 2027 P/E: 38–40x FY28E earnings

Why Premium Valuation is Justified:

Earnings CAGR (FY25–28E): 37%
Sector average: 15–20%

Operating Margins: 30–32%
Peer average: 18–22%

CDMO Exposure: 18% revenue, growing to 30%+
Peers: <10%

Order Visibility: FY27 (2.5 years)
Peers: 2–3 quarters

ROE Trajectory: 11.5% → 20.2% (FY25–28E)
Sector: 12–15%

Export Mix: 64–70%
Sector: 40–50%

PEG Ratio Analysis:

• Current P/E: 49.6x (FY26E)
• Earnings Growth Rate: 60–70% (FY26–27 estimated)
• PEG Ratio: 0.7–0.8x (vs. sector average 1.2–1.5x)

Interpretation: Stock is not expensive despite 50x P/E given exceptional growth trajectory

Downside Protection:

• Support Level: ₹4,500–4,600 (representing 40–42x FY27E conservative EPS of ₹110–115 with 25% margin assumption)
• Downside Risk: 12–15% from current levels in bear case scenario
• Risk-Reward: Asymmetric — 18–25% upside vs. 12–15% downside = Favorable 1.5:1 ratio

Investment Suitability

Ideal For:

• Growth investors seeking 20–25% annual returns over 2–3 year horizon
• Quality-focused investors prioritizing companies with improving return ratios and competitive moats
• Thematic exposure to:
(1) Pharma CDMO supply chain diversification
(2) Global refrigerant transition to low-GWP alternatives
(3) Make-in-India specialty chemicals

Not Suitable For:

• Value investors (P/B ~9.5x FY25)
• Income investors (0.4–0.5% dividend yield)
• Risk-averse investors (high valuation multiple)
• Short-term traders (requires 12–18 month thesis play-out)

Portfolio Allocation Guidance

• Aggressive Growth Portfolio: 5–8% allocation
• Balanced Growth Portfolio: 3–5% allocation
• Conservative Portfolio: 0–2% allocation

Key Risks to Monitor

Critical Risks (High Impact, Medium Probability):

1. CDMO target miss — failure to achieve $100mn FY27 revenue (20% probability)
2. Margin normalization — margins revert to 25–26% during capacity ramp-up (25% probability)
3. Customer concentration — European MSA customer disruption (15% probability)

Moderate Risks:

4. Capex execution delays (20% probability)
5. Valuation multiple compression amid sector re-rating (30% probability)
6. Working capital pressure requiring extra funding (25% probability)

Manageable Risks:

7. Currency volatility (export-heavy mix)
8. Raw material inflation
9. Regulatory changes impacting CDMO

Action Steps for Investors

For New Investors:

• Accumulate in ₹4,800–5,200 range
• Start with 50–60% position size
• Add on dips to ₹4,600–4,800
• Avoid chasing above ₹5,500 before Q3 FY26 results

For Existing Investors:

• HOLD and ADD on dips below ₹4,800
• Book partial profits above ₹6,200 pre-results
• Exit if stock breaks ₹4,200 or margins fall below 27%

Monitoring Calendar

• January 2026 — Q3 FY26 results (margin sustainability)
• May 2026 — FY26 annual results (execution + guidance)
• October 2026 — Q2 FY27 results (CDMO + capex progress)
• March 2027 — FY27 results ($100mn CDMO verdict)

Conclusion

Navin Fluorine International presents a compelling growth story at reasonable valuation for investors with 12–18 month investment horizon and moderate-high risk appetite. The company’s transformation into a high-margin specialty chemicals + pharma CDMO player is validated by:

• 32.5% operating margins
• 46% revenue growth
• ₹311.5 crore capacity expansion
• Visibility through FY27

While valuation appears elevated at 49.6x FY26E P/E, the 37% earnings CAGR projection through FY28 and PEG ratio of 0.7–0.8x suggest attractive risk-adjusted returns.

Investment Verdict: BUY with ₹5,930 target price (18–20% upside).
Accumulate on dips to ₹4,800–5,000 range. Monitor quarterly margins and CDMO progress closely.

Navin Fluorine (NAVINFLUOR) - 1 Year Price & Volume Chart: Stock surged 74.6% from ₹2,850 to ₹4,977 with significant volume spikes during Q2 FY26 results (Oct 2025) and capacity expansion announcements. Peak reached at ₹5,187 post-earnings.

Compliance & Disclaimers

This newsletter is for informational and educational purposes only. It does not constitute investment advice, recommendation, or solicitation to buy or sell securities. All data has been validated via two-source verification as per Oorjita's framework. Market conditions can change rapidly; past performance does not guarantee future results.

‍